Group I4: Nuclear Medicine Imaging
102 items with their schedule fees and Medicare benefits.
| Item | Fee | 75% | Out of hospital |
|---|---|---|---|
| 61310Cardiac imaging study using radiopharmaceutical agents to detect acute myocardial infarction or assess myocardial viability and perfusion. | $399.35 | $299.55 | $339.45 (85%) |
| 61313Imaging test using radioactive tracer to assess heart function, measure ejection fraction, and evaluate cardiac motion and blood flow. | $329.85 | $247.40 | $280.40 (85%) |
| 61314Gated cardiac blood pool imaging study (with or without intervention) or first pass blood flow/cardiac shunt assessment. | $456.70 | $342.55 | $388.20 (85%) |
| 61321Single rest myocardial perfusion SPECT study using Tc-99m to assess viable and non-viable myocardium in patients with left ventricular dysfunction and coronary artery disease, requested by a specialist, not within 24 months of previous study. | $357.70 | $268.30 | $304.05 (85%) |
| 61324Single photon emission tomography stress myocardial perfusion study for patients with cardiac ischaemia symptoms who cannot undergo or have failed stress echocardiography, requested by a specialist, with resting and exercise ECG monitoring; not withi… | $710.10 | $532.60 | $605.60 (85%) |
| 61325Rest myocardial perfusion study using Tl-201 SPECT to assess viable and non-viable myocardium in patients with left ventricular dysfunction and coronary artery disease, requested by specialist, limited to twice per 24 months (not within 24 months of… | $1,949.45 | $1,462.10 | $1,844.95 (85%) |
| 61328Lung perfusion imaging to assess blood flow distribution in the lungs, typically used to evaluate suspected pulmonary embolism or other cardiopulmonary conditions. | $247.50 | $185.65 | $210.40 (85%) |
| 61329Nuclear myocardial perfusion imaging with stress and rest phases for patients with cardiac ischaemia symptoms who cannot have adequate stress echocardiography due to body habitus, exercise inability, or prior failed test; includes ECG monitoring and… | $1,067.85 | $800.90 | $963.35 (85%) |
| 61333PET lung ventilation and perfusion imaging using Galligas and gallium-68 MAA when technetium-99m imaging (item 61348) is unavailable. | $443.35 | $332.55 | $376.85 (85%) |
| 61336PET brain imaging when technetium-99m is unavailable for the planned nuclear medicine scan. | $605.05 | $453.80 | $514.30 (85%) |
| 61340Nuclear medicine scan measuring air distribution in lungs using inhaled radioactive gas to diagnose ventilation problems or lung disease. | $275.10 | $206.35 | $233.85 (85%) |
| 61341Whole body PET bone imaging with delayed imaging, performed when Tc-99m bone studies are unavailable. | $600.70 | $450.55 | $510.60 (85%) |
| 61345Myocardial perfusion imaging with stress and rest protocols using single photon emission tomography for patients with cardiac ischaemia symptoms who cannot undergo stress echocardiography or have failed prior testing, requiring specialist referral an… | $1,067.85 | $800.90 | $963.35 (85%) |
| 61348Nuclear medicine imaging of lung blood flow and air movement using inhaled radioactive gas or aerosol to assess pulmonary perfusion and ventilation. | $482.05 | $361.55 | $409.75 (85%) |
| 61349Repeat myocardial perfusion imaging (stress/rest with SPECT) within 24 months of a prior similar study, following revascularisation, for evolving ischaemic symptoms inadequately controlled medically, when stress echo is unsuitable or failed; speciali… | $1,067.85 | $800.90 | $963.35 (85%) |
| 61353Radionuclide imaging of the liver and spleen using colloid to assess organ function, size, and detect lesions or abnormalities. | $420.40 | $315.30 | $357.35 (85%) |
| 61356Radionuclide imaging study using red blood cells to assess spleen or liver function and structure. | $427.10 | $320.35 | $363.05 (85%) |
| 61357Single-photon emission tomography myocardial perfusion scan for patients with cardiac ischaemia symptoms who cannot undergo stress echocardiography due to body habitus, exercise inability, or prior failed stress echo; includes resting ECG, continuous… | $710.10 | $532.60 | $605.60 (85%) |
| 61360Hepatobiliary imaging study to assess liver and bile duct function, including optional morphine administration or cholagogue pre-treatment. | $438.55 | $328.95 | $372.80 (85%) |
| 61361Hepatobiliary imaging with quantified function assessment after stimulation with a cholagogue, measuring bile flow and gallbladder ejection. | $501.70 | $376.30 | $426.45 (85%) |
| 61364Radiology service for diagnostic imaging to identify the source and extent of active bowel bleeding. | $540.40 | $405.30 | $459.35 (85%) |
| 61368Radionuclide imaging study to detect Meckel's diverticulum, a congenital remnant of the omphalomesenteric duct that may cause gastrointestinal bleeding or obstruction. | $242.60 | $181.95 | $206.25 (85%) |
| 61369Indium-labelled octreotide imaging with SPECT for suspected or confirmed gastro-entero-pancreatic endocrine tumours when biochemical evidence suggests disease but conventional imaging is negative/equivocal, or to exclude additional tumour sites befor… | $2,191.90 | $1,643.95 | $2,087.40 (85%) |
| 61372Radiographic imaging of the salivary glands and ducts using contrast medium to assess for obstruction, stones, or other pathology. | $242.60 | $181.95 | $206.25 (85%) |
| 61373Gastro-oesophageal reflux imaging study with optional delayed imaging performed on a separate day. | $532.50 | $399.40 | $452.65 (85%) |
| 61376Radiological study to assess oesophageal function and clearance of swallowed material, typically using fluoroscopy or other imaging to evaluate dysphagia or suspected motility disorders. | $155.85 | $116.90 | $132.50 (85%) |
| 61381Gastric emptying study using a single radioactive tracer to assess stomach function and rate of food movement into the small intestine. | $624.55 | $468.45 | $530.90 (85%) |
| 61383Imaging test measuring how quickly food and liquid leave the stomach using radioactive tracers, performed on the same day or separate days. | $679.50 | $509.65 | $577.60 (85%) |
| 61384Imaging study using radioactive tracer to measure how quickly food moves through the colon, used to diagnose motility disorders. | $747.80 | $560.85 | $643.30 (85%) |
| 61386Renal imaging study using radioisotope to assess kidney perfusion, function via renogram, or cortical uptake with computer analysis. | $361.55 | $271.20 | $307.35 (85%) |
| 61387Renal cortical imaging using single photon emission tomography with planar quantification to assess kidney function and structure. | $468.40 | $351.30 | $398.15 (85%) |
| 61389Nuclear medicine scan of one kidney with pre-procedure diuretic or ACE inhibitor injection to assess kidney function and perfusion. | $402.90 | $302.20 | $342.50 (85%) |
| 61390Renal imaging study performed after diuretic administration to assess kidney function and drainage, following an initial baseline image. | $445.80 | $334.35 | $378.95 (85%) |
| 61393Renal imaging study with baseline scan and repeat scan after ACE inhibitor provocation to assess kidney blood flow and function, related to a single referral episode. | $658.45 | $493.85 | $559.70 (85%) |
| 61394Single stress myocardial perfusion study with SPECT for patients with cardiac ischaemia symptoms, in Modified Monash 3-7 areas where stress echocardiography unavailable, requested by specialist, with continuous monitoring; not within 24 months of pre… | $710.10 | $532.60 | $605.60 (85%) |
| 61397Radiographic imaging study of the bladder and ureters, typically performed after injection of contrast medium to assess structure, function, and for detection of abnormalities. | $268.45 | $201.35 | $228.20 (85%) |
| 61398Myocardial perfusion imaging (stress/rest or stress/re-injection) with SPECT for cardiac ischaemia symptoms in rural/remote areas (MM3-7) where stress echo unavailable, requested by non-specialist GP, with continuous monitoring, not within 24 months… | $1,067.85 | $800.90 | $963.35 (85%) |
| 61402SPECT imaging of cerebral blood flow to assess brain perfusion, including planar imaging if needed. | $657.95 | $493.50 | $559.30 (85%) |
| 61406Combined stress and rest myocardial perfusion study with SPECT for patients with cardiac ischaemia symptoms, in regional areas without stress echo access, requested by specialist, with full monitoring; not within 24 months of prior similar imaging. | $1,067.85 | $800.90 | $963.35 (85%) |
| 61409Radionuclide imaging study tracking cerebrospinal fluid movement using Technetium 99m with imaging performed on 2 or more separate days. | $949.80 | $712.35 | $845.30 (85%) |
| 61410Repeat myocardial perfusion imaging (stress/rest with SPECT) for patients with evolving cardiac ischaemia symptoms after revascularisation, available only in rural areas (Modified Monash 3-7) without stress echo access, if prior imaging was done in l… | $1,067.85 | $800.90 | $963.35 (85%) |
| 61413Radiology study to assess whether a cerebrospinal fluid shunt is functioning properly and fluid is flowing through it as intended. | $245.70 | $184.30 | $208.85 (85%) |
| 61414Single photon emission tomography stress myocardial perfusion study for patients with cardiac ischaemia symptoms in rural/regional areas (Modified Monash 3-7) where stress echocardiography is unavailable, requested by a GP, with no prior study in 24… | $710.10 | $532.60 | $605.60 (85%) |
| 61421Whole body bone scan with blood flow, blood pool, and delayed imaging phases performed on a separate occasion. | $521.70 | $391.30 | $443.45 (85%) |
| 61425Whole-body bone imaging with SPECT, including blood flow, blood pool, and delayed imaging performed on a different day. | $653.15 | $489.90 | $555.20 (85%) |
| 61426Whole body radioisotope scan using radioactive iodine to detect thyroid cancer spread, metastases, or thyroid function abnormalities. | $603.30 | $452.50 | $512.85 (85%) |
| 61429Imaging using gallium radiopharmaceutical to scan the whole body for detection of infection, inflammation, malignancy or other pathology. | $1,636.50 | $1,227.40 | $1,532.00 (85%) |
| 61430Gallium whole body imaging with single photon emission tomography to detect infection, inflammation, or tumour. | $1,763.20 | $1,322.40 | $1,658.70 (85%) |
| 61433Whole body imaging scan using technetium-labeled cells to detect abnormalities in blood flow, infection, inflammation, or organ function. | $540.40 | $405.30 | $459.35 (85%) |
| 61434Whole body imaging using technetium-labelled cells with single photon emission tomography to detect infection or inflammation. | $669.20 | $501.90 | $568.85 (85%) |
| 61438Thallium whole body imaging study to assess myocardial perfusion, detect coronary artery disease, or evaluate cardiac viability in patients with known or suspected heart disease. | $2,323.50 | $1,742.65 | $2,219.00 (85%) |
| 61441Nuclear medicine scan of the entire skeleton using radioactive technetium-labelled agents to assess bone marrow distribution and function. | $532.50 | $399.40 | $452.65 (85%) |
| 61442Gallium scan with single photon emission tomography imaging 2 or more separate body regions to detect infection, inflammation or malignancy. | $1,864.20 | $1,398.15 | $1,759.70 (85%) |
| 61445Bone marrow imaging using radioactive technetium tracer to assess bone marrow function and detect localized abnormalities. | $311.85 | $233.90 | $265.10 (85%) |
| 61446Bone imaging scan using radioactive tracer to assess blood flow, blood pool and bone uptake, with option for repeat scan on a different day. | $362.70 | $272.05 | $308.30 (85%) |
| 61449Bone scintigraphy with SPECT imaging using approved agents, including blood flow and pool phases, with optional repeat imaging on a separate day. | $496.05 | $372.05 | $421.65 (85%) |
| 61450Localised gallium imaging study to detect infection, inflammation, or malignancy in a specific body region. | $1,478.30 | $1,108.75 | $1,373.80 (85%) |
| 61453Localised gallium imaging study using single photon emission tomography to detect infection, inflammation or malignancy in a specific body region. | $1,605.75 | $1,204.35 | $1,501.25 (85%) |
| 61454Nuclear medicine scan using technetium-labelled cells to image a specific body region for diagnosis or assessment of localised disease. | $378.55 | $283.95 | $321.80 (85%) |
| 61457Nuclear medicine scan using radioactive technetium tracer and single photon emission tomography to image a localised body area. | $511.55 | $383.70 | $434.85 (85%) |
| 61461Nuclear medicine imaging using thallium to assess localised areas of the body, typically for cardiac perfusion or tumour detection. | $2,165.70 | $1,624.30 | $2,061.20 (85%) |
| 61462Repeat nuclear medicine imaging (planar or SPECT) on the same day as initial scan if no extra radiopharmaceutical given and initial results were abnormal or equivocal. | $140.25 | $105.20 | $119.25 (85%) |
| 61466Imaging study using indium-111 to track cerebrospinal fluid movement, requiring scans on 2 or more separate days. | $5,100.85 | $3,825.65 | $4,996.35 (85%) |
| 61469Radionuclide imaging using injected radioactive tracer to visualize lymphatic system flow and function, typically for staging cancer or evaluating lymphedema. | $378.55 | $283.95 | $321.80 (85%) |
| 61473Thyroid ultrasound or imaging study performed on the right side, typically to evaluate thyroid nodules, enlargement, or other structural abnormalities. | $190.75 | $143.10 | $162.15 (85%) |
| 61480Radiological imaging study of the parathyroid glands to assess parathyroid gland size, location, and function in patients with suspected parathyroid disease. | $420.65 | $315.50 | $357.60 (85%) |
| 61485Adrenal imaging using single photon emission tomography to assess adrenal function and detect abnormalities like tumours or hyperplasia. | $3,658.00 | $2,743.50 | $3,553.50 (85%) |
| 61495Radiological imaging study of the tear drainage system, typically using contrast medium to identify blockages or abnormalities in the lacrimal ducts. | $242.60 | $181.95 | $206.25 (85%) |
| 61499Nuclear medicine scan to assess blood flow to organs via intra-arterial injection or to evaluate LeVeen shunt function, performed with radiotracers. | $275.10 | $206.35 | $233.85 (85%) |
| 61505CT scan performed simultaneously with SPECT or PET of the same body area for localisation or attenuation correction, with no separate diagnostic report. | $100.00 | $75.00 | $85.00 (85%) |
| 61523Whole body FDG PET imaging to evaluate a solitary lung nodule that cannot be biopsied or where biopsy has failed. | $953.00 | $714.75 | $848.50 (85%) |
| 61524PET scan of the whole body using FDG tracer for staging of advanced (Stage III) breast cancer in patients suitable for active treatment. | $953.00 | $714.75 | $848.50 (85%) |
| 61525FDG PET scan of the whole body to evaluate suspected metastatic, local or regional recurrence of breast cancer in patients suitable for active therapy. | $953.00 | $714.75 | $848.50 (85%) |
| 61527PET whole body imaging when gallium-67 imaging is unavailable for oncology, infection, or inflammation assessment. | $752.35 | $564.30 | $647.85 (85%) |
| 61528Whole body PSMA PET scan to assess eligibility for Lutetium 177 PSMA therapy in metastatic castrate-resistant prostate cancer patients who have progressed on prior taxane chemotherapy and androgen receptor signalling inhibitor. | $1,300.00 | $975.00 | $1,195.50 (85%) |
| 61529FDG PET scan of whole body to stage non-small cell lung cancer in patients being considered for curative surgery or radiotherapy. | $953.00 | $714.75 | $848.50 (85%) |
| 61530Whole body 68Ga-DOTA-somatostatin receptor PET imaging for staging surgically incurable neuroendocrine tumours, assessing somatostatin receptor expression before peptide receptor radionuclide therapy, evaluating therapy response, or detecting recurre… | $953.00 | $714.75 | $848.50 (85%) |
| 61538FDG PET brain imaging to assess for residual or recurrent malignant brain tumour in patients suitable for further active therapy, following or during definitive treatment. | $901.00 | $675.75 | $796.50 (85%) |
| 61541FDG PET scan of the whole body to detect residual, metastatic or recurrent colorectal cancer after initial treatment, in patients fit for active therapy. | $953.00 | $714.75 | $848.50 (85%) |
| 61553FDG PET whole body scan to detect metastatic or recurrent melanoma in patients suitable for active treatment, performed after initial therapy. | $999.00 | $749.25 | $894.50 (85%) |
| 61559FDG PET imaging of the brain to assess seizure foci in refractory epilepsy patients being considered for surgical treatment. | $918.00 | $688.50 | $813.50 (85%) |
| 61560FDG PET brain scan for Alzheimer's disease diagnosis when clinical assessment by a specialist is equivocal, including quantitative comparison to normal reference database; limited to 3 times lifetime and not within 12 months of previous similar scan. | $605.05 | $453.80 | $514.30 (85%) |
| 61563Whole body PSMA PET imaging for initial staging of intermediate to high-risk prostate cancer in treatment-naive patients considered for curative locoregional therapy, limited to once per lifetime. | $1,300.00 | $975.00 | $1,195.50 (85%) |
| 61564PSMA PET scan of whole body to restage recurrent prostate cancer in patients who've had prior local treatment and may be suitable for further local therapy; available twice in lifetime. | $1,300.00 | $975.00 | $1,195.50 (85%) |
| 61565FDG PET scan of whole body to detect residual, metastatic or recurrent ovarian cancer after initial therapy in patients eligible for active treatment. | $953.00 | $714.75 | $848.50 (85%) |
| 61571FDG PET scan of the whole body for initial staging of cervical cancer (FIGO stage IB2 or higher) before radical radiation or combined therapy with curative intent. | $953.00 | $714.75 | $848.50 (85%) |
| 61575FDG PET scan of the whole body to stage local recurrence of cervical cancer in patients being considered for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. | $953.00 | $714.75 | $848.50 (85%) |
| 61577FDG PET scan of the whole body to stage oesophageal or gastro-oesophageal junction cancer in patients fit for active treatment. | $953.00 | $714.75 | $848.50 (85%) |
| 61598FDG PET scan of the whole body to stage newly diagnosed or recurrent head and neck cancer that has been confirmed by biopsy. | $953.00 | $714.75 | $848.50 (85%) |
| 61604FDG PET scan of the whole body to evaluate suspected residual head and neck cancer after definitive treatment in patients suitable for active therapy. | $953.00 | $714.75 | $848.50 (85%) |
| 61610FDG PET scan of the whole body to evaluate metastatic squamous cell carcinoma of unknown primary origin presenting with cervical lymph node involvement. | $953.00 | $714.75 | $848.50 (85%) |
| 61612Initial whole body FDG PET scan for staging FDG-avid cancers in patients suitable for active therapy where results would likely change management; once per cancer diagnosis. | $953.00 | $714.75 | $848.50 (85%) |
| 61614FDG PET whole body scan to detect residual, metastatic or recurrent cancer post-treatment in patients suitable for active therapy, limited to typically FDG-avid cancers. | $953.00 | $714.75 | $848.50 (85%) |
| 61620FDG PET scan of the whole body to stage newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma. | $953.00 | $714.75 | $848.50 (85%) |
| 61622FDG PET scan of the whole body to evaluate treatment response in Hodgkin or non-Hodgkin lymphoma during or within three months after completing first-line therapy. | $953.00 | $714.75 | $848.50 (85%) |
| 61628Whole body FDG PET scan to assess extent of disease after confirmed recurrence of Hodgkin or non-Hodgkin lymphoma. | $953.00 | $714.75 | $848.50 (85%) |
| 61632FDG PET whole body scan to evaluate chemotherapy response in Hodgkin or non-Hodgkin lymphoma patients being considered for haemopoietic stem cell transplantation. | $953.00 | $714.75 | $848.50 (85%) |
| 61640Whole body FDG-PET scan for initial staging of biopsy-proven bone or soft tissue sarcoma (excluding GIST) when conventional staging suggests potential curability. | $999.00 | $749.25 | $894.50 (85%) |
| 61644PET myocardial perfusion study to assess non-viable myocardium in patients with left ventricular dysfunction and coronary artery disease when Tl-201 unavailable, performed with Tc-99m study, specialist-requested, limited to twice per 24 months. | $329.00 | $246.75 | $279.65 (85%) |
| 61646FDG PET scan of whole body to assess for residual or recurrent sarcoma (excluding GIST) after initial treatment, to evaluate eligibility for curative therapy options. | $999.00 | $749.25 | $894.50 (85%) |
| 61647PET scan using 68Ga DOTA peptide to detect gastroenteropancreatic neuroendocrine tumours when suspected by biochemical markers with negative imaging, or to exclude additional disease sites in confirmed surgically-treatable tumours. | $953.00 | $714.75 | $848.50 (85%) |
| 61650Nuclear medicine scan of long bones and feet to detect bone infection, available only if ex vivo white blood cell scanning is unavailable and no other infection sites are being investigated. | $955.50 | $716.65 | $851.00 (85%) |